These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 22471707)

  • 1. Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeutics.
    Stone A; Sutherland RL; Musgrove EA
    Crit Rev Oncog; 2012; 17(2):175-98. PubMed ID: 22471707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promotion of apoptosis in cancer cells by selective purine-derived pharmacological CDK inhibitors: one outcome, many mechanisms.
    Węsierska-Gądek J; Maurer M
    Curr Pharm Des; 2011; 17(3):256-71. PubMed ID: 21348827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
    Di Giovanni C; Novellino E; Chilin A; Lavecchia A; Marzaro G
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1215-30. PubMed ID: 27606939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
    Chohan TA; Qayyum A; Rehman K; Tariq M; Akash MSH
    Biomed Pharmacother; 2018 Nov; 107():1326-1341. PubMed ID: 30257348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
    Santo L; Siu KT; Raje N
    Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting cyclin-dependent kinases in anti-neoplastic therapy.
    Bruyère C; Meijer L
    Curr Opin Cell Biol; 2013 Dec; 25(6):772-9. PubMed ID: 24011867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
    Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M
    Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.
    Wesierska-Gadek J; Schmid G
    Expert Opin Investig Drugs; 2006 Jan; 15(1):23-38. PubMed ID: 16370931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in the evaluation of CDK inhibitors as anti-tumor agents.
    McInnes C
    Drug Discov Today; 2008 Oct; 13(19-20):875-81. PubMed ID: 18639646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
    Malínková V; Vylíčil J; Kryštof V
    Expert Opin Ther Pat; 2015; 25(9):953-70. PubMed ID: 26161698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors.
    Collins I; Garrett MD
    Curr Opin Pharmacol; 2005 Aug; 5(4):366-73. PubMed ID: 15964238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel potent pharmacological cyclin-dependent kinase inhibitors.
    Węsierska-Gądek J; Chamrád I; Kryštof V
    Future Med Chem; 2009 Dec; 1(9):1561-81. PubMed ID: 21425979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.
    Abate AA; Pentimalli F; Esposito L; Giordano A
    Expert Opin Investig Drugs; 2013 Jul; 22(7):895-906. PubMed ID: 23735075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecules inducing specific cyclin-dependent kinase degradation and their possible use in cancer therapy.
    Zheng M; Zhang XY; Chen W; Xia F; Yang H; Yuan K; Yang P
    Future Med Chem; 2024 Feb; 16(4):369-388. PubMed ID: 38288571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors.
    Pitts TM; Davis SL; Eckhardt SG; Bradshaw-Pierce EL
    Pharmacol Ther; 2014 May; 142(2):258-69. PubMed ID: 24362082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?
    Jorda R; Hendrychová D; Voller J; Řezníčková E; Gucký T; Kryštof V
    J Med Chem; 2018 Oct; 61(20):9105-9120. PubMed ID: 30234987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting cell cycle kinases for cancer therapy.
    de Cárcer G; Pérez de Castro I; Malumbres M
    Curr Med Chem; 2007; 14(9):969-85. PubMed ID: 17439397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin-dependent kinases in cancer: Role, regulation, and therapeutic targeting.
    Gupta A; Dagar G; Chauhan R; Sadida HQ; Almarzooqi SK; Hashem S; Uddin S; Macha MA; Akil ASA; Pandita TK; Bhat AA; Singh M
    Adv Protein Chem Struct Biol; 2023; 135():21-55. PubMed ID: 37061333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.